Target-Specific Delivery of Gold and Ruthenium Complexes to Cancer Cells: Where Are We?
A special issue of Chemistry (ISSN 2624-8549). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 442
Special Issue Editors
Interests: organometallic/inorganic chemistry; peptide chemistry; metal–peptide conjugates; interaction studies with biomolecules; anticancer drug design and development; drug delivery; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals
Interests: molecular imaging; nuclear chemistry; radiopharmaceutical chemistry; theranostics; metallodrugs; peptides; targeted radionuclide therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Cancer is the second leading cause of death worldwide, and it is expected that in 20 years, there will be ~26 million new cancer cases. Despite the progress made in the last few years, cancer treatment, mainly focused on radiation therapy and chemotherapy, presents low therapeutic indices and a wide spectrum of severe side-effects, in part due to the little or no selectivity of drugs for cancer cells over nontumoral cells. Therefore, the need for alternative therapeutic options with improved selectivity is critical.
Following the clinical success achieved with platinum complexes, the search for metallodrugs with improved therapeutic properties has been extremely active within the bioinorganic/organometallic chemistry community. Among the large number of metal complexes with considerable anticancer properties, gold and ruthenium complexes are amongst the most promising alternatives. Nevertheless, this topic still remains a challenge to all scientists, especially those involved in the design of innovative metal-based target specific agents.
This Special Issue of Molecules welcomes original research articles, communications, and review articles dealing with major advancements and challenges of metallodrug discovery for cancer treatment. It will focus on design, identification, and evaluation of novel gold and ruthenium anticancer agents, biological targets, and targeting approaches.
You may choose our Joint Special Issue in Molecules.
Dr. Tânia S. Morais
Prof. Dr. João D. G. Correia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Chemistry is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug discovery
- drug design
- anticancer
- metallodrugs
- ruthenium
- gold
- targeting
- selectivity
- biological targets
- therapeutic approaches
